Sanuwave Health (Alpharetta, Ga.) is still in the game after it revealed top line data from a pivotal phase III, investigational device exemption supplemental clinical trial evaluating its Dermapace diabetic foot ulcer treatment technology. While the company failed to meet its primary endpoint of healing and wound closure at 12 weeks, it did show the device had highly significant results in healing wounds at 20 weeks.